Late-breaking abstracts related to #ADCs at #ESMO25 (LBA16 and LBA21 have not yet been released). >10% of LBAs are on ADCs!

raffcolo's tweet image. Late-breaking abstracts related to #ADCs at #ESMO25

(LBA16 and LBA21 have not yet been released). 

>10% of LBAs are on ADCs!

ADCs stole the show at #ESMO25 and they’ll dominate #ASCO25 too 💥 Smarter linkers, safer payloads, and dual-target precision are changing cancer therapy. @OncoAlert @brunolarvol @Dr_Doc_ @FDAOncology @OncBrothers @JCO_ASCO @myESMO #ADCs #CancerTherapy #ASCO25

NeerajResearch's tweet image. ADCs stole the show at #ESMO25  and they’ll dominate #ASCO25 too 💥
Smarter linkers, safer payloads, and dual-target precision are changing cancer therapy.
@OncoAlert @brunolarvol @Dr_Doc_ @FDAOncology @OncBrothers @JCO_ASCO @myESMO
#ADCs #CancerTherapy #ASCO25

No podemos finalizar por hoy sin mencionar la excelente labor como moderadora de la Dra. María Isabel Gallegos (Hospital General de Segovia). 💕 A lo largo de estos días continuaremos compartiendo lo más destacado de la reunión. #MamaCentroADCs2025 #ADCs

MamaCentro's tweet image. No podemos finalizar por hoy sin mencionar la excelente labor como moderadora de la Dra. María Isabel Gallegos (Hospital General de Segovia). 💕

A lo largo de estos días continuaremos compartiendo lo más destacado de la reunión.

#MamaCentroADCs2025
#ADCs

Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology

CarmineDeA1's tweet image. Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 
🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology
CarmineDeA1's tweet image. Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 
🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology
CarmineDeA1's tweet image. Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 
🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology
CarmineDeA1's tweet image. Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 
🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology

What an amazing Plenary Session on #ADCs at #Targets25! 🔬✨@AACR Incredible discussions on dual payload ADCs, combo strategies with targeted therapies, and bridging biomarker gaps for smarter patient selection. Honored to be part of it—thank you to the organizers for the…

BrunaPellini's tweet image. What an amazing Plenary Session on #ADCs at #Targets25! 🔬✨@AACR 
Incredible discussions on dual payload ADCs, combo strategies with targeted therapies, and bridging biomarker gaps for smarter patient selection.

Honored to be part of it—thank you to the organizers for the…
BrunaPellini's tweet image. What an amazing Plenary Session on #ADCs at #Targets25! 🔬✨@AACR 
Incredible discussions on dual payload ADCs, combo strategies with targeted therapies, and bridging biomarker gaps for smarter patient selection.

Honored to be part of it—thank you to the organizers for the…
BrunaPellini's tweet image. What an amazing Plenary Session on #ADCs at #Targets25! 🔬✨@AACR 
Incredible discussions on dual payload ADCs, combo strategies with targeted therapies, and bridging biomarker gaps for smarter patient selection.

Honored to be part of it—thank you to the organizers for the…

From @myESMO advanced course on #ADCs meet the new kids on the block: ✅ Bi-specific/Bi-paratopic ADCs ✅ PDCs with peptide masks allowing payload cleavage by tumor proteases ✅ ISACS with TLR or STING agonist payload ✅ DACs degrading target through proteasome ubiquitin…

g_mountzios's tweet image. From @myESMO  advanced course on #ADCs meet the new kids on the block:

✅ Bi-specific/Bi-paratopic ADCs
✅ PDCs with peptide masks allowing payload cleavage by tumor proteases
✅ ISACS with TLR or STING agonist payload
✅ DACs degrading target  through proteasome ubiquitin…
g_mountzios's tweet image. From @myESMO  advanced course on #ADCs meet the new kids on the block:

✅ Bi-specific/Bi-paratopic ADCs
✅ PDCs with peptide masks allowing payload cleavage by tumor proteases
✅ ISACS with TLR or STING agonist payload
✅ DACs degrading target  through proteasome ubiquitin…
g_mountzios's tweet image. From @myESMO  advanced course on #ADCs meet the new kids on the block:

✅ Bi-specific/Bi-paratopic ADCs
✅ PDCs with peptide masks allowing payload cleavage by tumor proteases
✅ ISACS with TLR or STING agonist payload
✅ DACs degrading target  through proteasome ubiquitin…
g_mountzios's tweet image. From @myESMO  advanced course on #ADCs meet the new kids on the block:

✅ Bi-specific/Bi-paratopic ADCs
✅ PDCs with peptide masks allowing payload cleavage by tumor proteases
✅ ISACS with TLR or STING agonist payload
✅ DACs degrading target  through proteasome ubiquitin…

@FawziAbuRous⁩ gives a great overview on #ADCs in Lung Cancer #MLS_DC25@RamSubraMD

NaglaAKarimMD's tweet image. ⁦@FawziAbuRous⁩ gives a great overview on #ADCs in Lung Cancer #MLS_DC25 ⁦@RamSubraMD⁩
NaglaAKarimMD's tweet image. ⁦@FawziAbuRous⁩ gives a great overview on #ADCs in Lung Cancer #MLS_DC25 ⁦@RamSubraMD⁩

While #ADCs are moving to earlier lines and across all subtypes, we should always keep in mind their unique #toxicity profiles and management strategies-@PTarantinoMD @myESMO #ESMO25 @Larvol @oncodaily @ozdogan_md

Dr_ElvinaA's tweet image. While #ADCs are moving to earlier lines and across all subtypes, we should always keep in mind their unique #toxicity profiles and management strategies-@PTarantinoMD 

@myESMO #ESMO25 @Larvol @oncodaily @ozdogan_md
Dr_ElvinaA's tweet image. While #ADCs are moving to earlier lines and across all subtypes, we should always keep in mind their unique #toxicity profiles and management strategies-@PTarantinoMD 

@myESMO #ESMO25 @Larvol @oncodaily @ozdogan_md

Empezamos con el Dr. Juan Cristóbal Sánchez y su ABC: "Antes de los ADCs la eficacia del tratamiento del cáncer de mama triple negativo era bastante limitada". #ADCs #CancerdeMamaTripleNegativo

MamaCentro's tweet image. Empezamos con el Dr. Juan Cristóbal Sánchez y su ABC:   

"Antes de los ADCs la eficacia del tratamiento del cáncer de mama triple negativo era bastante limitada".

#ADCs
#CancerdeMamaTripleNegativo

Vamos con la última ponencia de la tarde, la Dra. Ana María García Tapiador y su ABC: "Podemos decir que cualquier paciente con cáncer de mama metastásico sería candidata a un ADC en algun momento". #ADCs #CancerdeMamaMetastasico #MamaCentroADCs2025

MamaCentro's tweet image. Vamos con la última ponencia de la tarde, la Dra. Ana María García Tapiador y su ABC: 

"Podemos decir que cualquier paciente con cáncer de mama metastásico sería candidata a un ADC en algun momento".

#ADCs
#CancerdeMamaMetastasico
#MamaCentroADCs2025

The case for short-lived certificates in enterprise environments. #identity #pki #adcs #security rmhci.co/3SgmZqZ

richardhicks's tweet image. The case for short-lived certificates in enterprise environments. #identity #pki #adcs #security rmhci.co/3SgmZqZ

▫️#ASCO25: #ADCs in Lung Cancer Rapid Evolution with a robust lineup of ADC trials across 1L, 2L, and neoadjuvant NSCLC and SCLC settings. 🔹 Key Targets: TROP2, c-MET, HER3, B7H3 🔹 Payloads: TOPOi, TUBi, 🔹 Settings: EGFRm, MET overexpressed, chemo-refractory ➡️ Highlights:…

ADesaiMD's tweet image. ▫️#ASCO25: #ADCs in Lung Cancer Rapid Evolution with a robust lineup of ADC trials across 1L, 2L, and neoadjuvant NSCLC and SCLC settings.

🔹 Key Targets: TROP2, c-MET, HER3, B7H3
🔹 Payloads: TOPOi, TUBi, 
🔹 Settings: EGFRm, MET overexpressed, chemo-refractory

➡️ Highlights:…

Turno del Dr. Manuel Alva y su ABC: "Cuando hablamos de ADCs en cáncer de mama HER2+ hablamos de Trastuzumab Deruxtecan". #ADCs #CancerdeMamaHER2Positivo #MamaCentroADCs2025

MamaCentro's tweet image. Turno del Dr. Manuel Alva y su ABC: 

"Cuando hablamos de ADCs en cáncer de mama HER2+ hablamos de Trastuzumab Deruxtecan".

#ADCs
#CancerdeMamaHER2Positivo
#MamaCentroADCs2025

At #ESMO25, we're presenting new data across targeted precision therapies in #oncology. From antibody-drug conjugates (#ADCs) to biomarker-driven therapies, we're working to transform care for patients with high unmet needs. Read more: abbv.ie/fb5efe


Student Love ❤ | CESP - ADCS Edition From practice labs to exam success - mastering AD CS! #CESP #ADCS #ActiveDirectory #RedTeam #CyberSecurity #CareerGrowth #AlteredSecurity

AlteredSecurity's tweet image. Student Love ❤ | CESP - ADCS Edition
From practice labs to exam success - mastering AD CS!

#CESP #ADCS #ActiveDirectory #RedTeam #CyberSecurity #CareerGrowth #AlteredSecurity

A state-of-the-art session by @tompowles1 , he truly put his heart into it. From EV+pembro transforming urothelial cancer, to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L bladder cancer, NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers. #ESMO25 #ADCs @myESMO

DrChoueiri's tweet image. A state-of-the-art session by @tompowles1 , he truly put his heart into it. From EV+pembro transforming urothelial cancer, to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L bladder cancer, NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers.
#ESMO25 #ADCs @myESMO…
DrChoueiri's tweet image. A state-of-the-art session by @tompowles1 , he truly put his heart into it. From EV+pembro transforming urothelial cancer, to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L bladder cancer, NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers.
#ESMO25 #ADCs @myESMO…
DrChoueiri's tweet image. A state-of-the-art session by @tompowles1 , he truly put his heart into it. From EV+pembro transforming urothelial cancer, to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L bladder cancer, NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers.
#ESMO25 #ADCs @myESMO…
DrChoueiri's tweet image. A state-of-the-art session by @tompowles1 , he truly put his heart into it. From EV+pembro transforming urothelial cancer, to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L bladder cancer, NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers.
#ESMO25 #ADCs @myESMO…

Study Highlights: Are #ADCs replacing chemo in breast cancer? #TDXd & SG show superior PFS in multiple subtypes—#DESTINYBreast09, ASCENT-07, and others could redefine frontline & adjuvant care. bit.ly/4mCyVS0 #BreastCancer @PTarantinoMD


Such an important 🔑 initiative to provide the latest information for patients and their care partners impacted by #SCLC! In this session, we discuss everything related to antibody-drug conjugates (#ADCs) & their role in SCLC: 🧑‍🔬 MOA: biological chemo “missile” 🎯 Targets:…

🎬 Exciting behind-the-scenes moment! Brittany recorded the Small Cell Lung Cancer Patient Education Program 2025–26 with Dr. @drshieldsmd today. This new video series will bring patients and caregivers the latest information about small cell lung cancer in an easy-to-understand…

cancerGRACE's tweet image. 🎬 Exciting behind-the-scenes moment!
Brittany recorded the Small Cell Lung Cancer Patient Education Program 2025–26 with Dr. @drshieldsmd today.

This new video series will bring patients and caregivers the latest information about small cell lung cancer in an easy-to-understand…


No podemos finalizar por hoy sin mencionar la excelente labor como moderadora de la Dra. María Isabel Gallegos (Hospital General de Segovia). 💕 A lo largo de estos días continuaremos compartiendo lo más destacado de la reunión. #MamaCentroADCs2025 #ADCs

MamaCentro's tweet image. No podemos finalizar por hoy sin mencionar la excelente labor como moderadora de la Dra. María Isabel Gallegos (Hospital General de Segovia). 💕

A lo largo de estos días continuaremos compartiendo lo más destacado de la reunión.

#MamaCentroADCs2025
#ADCs

Vamos con la última ponencia de la tarde, la Dra. Ana María García Tapiador y su ABC: "Podemos decir que cualquier paciente con cáncer de mama metastásico sería candidata a un ADC en algun momento". #ADCs #CancerdeMamaMetastasico #MamaCentroADCs2025

MamaCentro's tweet image. Vamos con la última ponencia de la tarde, la Dra. Ana María García Tapiador y su ABC: 

"Podemos decir que cualquier paciente con cáncer de mama metastásico sería candidata a un ADC en algun momento".

#ADCs
#CancerdeMamaMetastasico
#MamaCentroADCs2025

Turno del Dr. Manuel Alva y su ABC: "Cuando hablamos de ADCs en cáncer de mama HER2+ hablamos de Trastuzumab Deruxtecan". #ADCs #CancerdeMamaHER2Positivo #MamaCentroADCs2025

MamaCentro's tweet image. Turno del Dr. Manuel Alva y su ABC: 

"Cuando hablamos de ADCs en cáncer de mama HER2+ hablamos de Trastuzumab Deruxtecan".

#ADCs
#CancerdeMamaHER2Positivo
#MamaCentroADCs2025

Empezamos con el Dr. Juan Cristóbal Sánchez y su ABC: "Antes de los ADCs la eficacia del tratamiento del cáncer de mama triple negativo era bastante limitada". #ADCs #CancerdeMamaTripleNegativo

MamaCentro's tweet image. Empezamos con el Dr. Juan Cristóbal Sánchez y su ABC:   

"Antes de los ADCs la eficacia del tratamiento del cáncer de mama triple negativo era bastante limitada".

#ADCs
#CancerdeMamaTripleNegativo

La Dra. Anabel Ballesteros presentando "El ABC de los ADCs". Arrancamos! #MamaCentroADCs2025 #CancerdeMama #ADCs #Oncologia #DivulgacionCientifica #FormacionOncologica

MamaCentro's tweet image. La Dra. Anabel Ballesteros presentando "El ABC de los ADCs". Arrancamos!
#MamaCentroADCs2025

#CancerdeMama #ADCs #Oncologia #DivulgacionCientifica #FormacionOncologica

What makes an ADC truly effective? In Part 2, we decode the chemistry behind precision—linkers, antibodies & payloads working in harmony. Read more 👉 lnkd.in/gBdkD3xX #ADCs #TargetedTherapy #CentellaAI

CentellaAi's tweet image. What makes an ADC truly effective?

In Part 2, we decode the chemistry behind precision—linkers, antibodies & payloads working in harmony.

Read more 👉 lnkd.in/gBdkD3xX
#ADCs #TargetedTherapy #CentellaAI

“Antibody–Drug Conjugates in Small-Cell #LungCancer: Present-Day Status and Promises” in @OncJournal explores the promise of #ADCs while tackling challenges. Thrilled to see @triparnasen & colleagues leading this important work in SCLC #research!🚀 @OhioStateMedOnc @OSUCCC_James

Thrilled to share our latest work in @OncJournal: “Antibody–Drug Conjugates in Small-Cell Lung Cancer: Present-Day Status and Promises”. Despite early response signals, challenges such as #resistance, #antigen #heterogeneity, and #toxicity persist, and innovation in #payloads,…



Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors bit.ly/4p5ysbB $AKTX #AntibodyDrugConjugates #ADCs #Oncology

AkariTX's tweet image. Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

bit.ly/4p5ysbB 
$AKTX #AntibodyDrugConjugates #ADCs #Oncology…

ADCs stole the show at #ESMO25 and they’ll dominate #ASCO25 too 💥 Smarter linkers, safer payloads, and dual-target precision are changing cancer therapy. @OncoAlert @brunolarvol @Dr_Doc_ @FDAOncology @OncBrothers @JCO_ASCO @myESMO #ADCs #CancerTherapy #ASCO25

NeerajResearch's tweet image. ADCs stole the show at #ESMO25  and they’ll dominate #ASCO25 too 💥
Smarter linkers, safer payloads, and dual-target precision are changing cancer therapy.
@OncoAlert @brunolarvol @Dr_Doc_ @FDAOncology @OncBrothers @JCO_ASCO @myESMO
#ADCs #CancerTherapy #ASCO25

Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology

CarmineDeA1's tweet image. Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 
🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology
CarmineDeA1's tweet image. Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 
🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology
CarmineDeA1's tweet image. Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 
🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology
CarmineDeA1's tweet image. Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 
🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology

The evolution of HER2-targeted therapy, particularly with #ADCs like #Enhertu, marks significant progress in #breastcancer treatment. However, acquired resistance remains a key obstacle to patient survival. Discover our JIMT-1-Enhertu-R resistance model: buff.ly/yXgoqCY

GPharmatech's tweet image. The evolution of HER2-targeted therapy, particularly with #ADCs like #Enhertu, marks significant progress in #breastcancer treatment. However, acquired resistance remains a key obstacle to patient survival. Discover our JIMT-1-Enhertu-R resistance model: buff.ly/yXgoqCY

There’s still time - Silver Sponsors at #NCASC benefit from high-visibility branding on the official conference app + every attendee badge. Seen. Remembered. Respected. Apply now: orlo.uk/4fLow #ADASS #ADCS #LocalGov #SocialCare #ChildrensServices #PublicHealth

LGAcomms's tweet image. There’s still time - Silver Sponsors at #NCASC benefit from high-visibility branding on the official conference app + every attendee badge. Seen. Remembered. Respected. 

Apply now: orlo.uk/4fLow 

#ADASS #ADCS #LocalGov #SocialCare #ChildrensServices #PublicHealth

ADC (Antibody-Drug Conjugate) development is an exciting & complex area in biotherapeutics right now. The journey from concept to market is fraught with challenges but also opportunities for innovation. #Biotherapeutics #ADCs #rowlandtalent paiger.link/1358366624

rowland_talent's tweet image. ADC (Antibody-Drug Conjugate) development is an exciting & complex area in biotherapeutics right now. The journey from concept to market is fraught with challenges but also opportunities for innovation. 
#Biotherapeutics #ADCs  #rowlandtalent
 paiger.link/1358366624

Late-breaking abstracts related to #ADCs at #ESMO25 (LBA16 and LBA21 have not yet been released). >10% of LBAs are on ADCs!

raffcolo's tweet image. Late-breaking abstracts related to #ADCs at #ESMO25

(LBA16 and LBA21 have not yet been released). 

>10% of LBAs are on ADCs!

Locksmith 2024.10 is out with quality updates and improved detections for ESC8 and ESC3 condition 2. Have you double-checked your Active Directory Certificate Services templates yet? #ADCS #PKI #WindowsServer #ActiveDirectory #PowerShell github.com/TrimarcJake/Lo…

SamErde's tweet image. Locksmith 2024.10 is out with quality updates and improved detections for ESC8 and ESC3 condition 2. Have you double-checked your Active Directory Certificate Services templates yet? #ADCS #PKI #WindowsServer #ActiveDirectory #PowerShell
github.com/TrimarcJake/Lo…

Exclente sesión con expertos de Colombia 🇨🇴... Generando algoritmos de tratamiento de #EA #ADCs en #CáncerDeVejiga #EnfortumabVedotin @zapatalaguadomd

Martin_AngelMD's tweet image. Exclente sesión con expertos de Colombia 🇨🇴... Generando algoritmos de tratamiento de #EA  #ADCs en #CáncerDeVejiga #EnfortumabVedotin 
 @zapatalaguadomd
Martin_AngelMD's tweet image. Exclente sesión con expertos de Colombia 🇨🇴... Generando algoritmos de tratamiento de #EA  #ADCs en #CáncerDeVejiga #EnfortumabVedotin 
 @zapatalaguadomd

Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology

CarmineDeA1's tweet image. Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 
🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology
CarmineDeA1's tweet image. Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 
🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology
CarmineDeA1's tweet image. Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 
🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology
CarmineDeA1's tweet image. Honored to have discussed #ADCs in HER2+ ABC at #ABC8 in Lisbon 😊 A great moment of scientific exchange on the current and future role of ADCs in patient care. 
🙏🏻 Grateful to an exceptional faculty and organizers for this inspiring experience #BreastCancer #Oncology

While #ADCs are moving to earlier lines and across all subtypes, we should always keep in mind their unique #toxicity profiles and management strategies-@PTarantinoMD @myESMO #ESMO25 @Larvol @oncodaily @ozdogan_md

Dr_ElvinaA's tweet image. While #ADCs are moving to earlier lines and across all subtypes, we should always keep in mind their unique #toxicity profiles and management strategies-@PTarantinoMD 

@myESMO #ESMO25 @Larvol @oncodaily @ozdogan_md
Dr_ElvinaA's tweet image. While #ADCs are moving to earlier lines and across all subtypes, we should always keep in mind their unique #toxicity profiles and management strategies-@PTarantinoMD 

@myESMO #ESMO25 @Larvol @oncodaily @ozdogan_md

The case for short-lived certificates in enterprise environments. #identity #pki #adcs #security rmhci.co/3SgmZqZ

richardhicks's tweet image. The case for short-lived certificates in enterprise environments. #identity #pki #adcs #security rmhci.co/3SgmZqZ

@FawziAbuRous⁩ gives a great overview on #ADCs in Lung Cancer #MLS_DC25@RamSubraMD

NaglaAKarimMD's tweet image. ⁦@FawziAbuRous⁩ gives a great overview on #ADCs in Lung Cancer #MLS_DC25 ⁦@RamSubraMD⁩
NaglaAKarimMD's tweet image. ⁦@FawziAbuRous⁩ gives a great overview on #ADCs in Lung Cancer #MLS_DC25 ⁦@RamSubraMD⁩

And the @SPR1882 is underway and running smoothly, from #history so far to now #NDEs and #ADCs

CallumECooper's tweet image. And the @SPR1882 is underway and running smoothly, from #history so far to now #NDEs and #ADCs
CallumECooper's tweet image. And the @SPR1882 is underway and running smoothly, from #history so far to now #NDEs and #ADCs

ADCs stole the show at #ESMO25 and they’ll dominate #ASCO25 too 💥 Smarter linkers, safer payloads, and dual-target precision are changing cancer therapy. @OncoAlert @brunolarvol @Dr_Doc_ @FDAOncology @OncBrothers @JCO_ASCO @myESMO #ADCs #CancerTherapy #ASCO25

NeerajResearch's tweet image. ADCs stole the show at #ESMO25  and they’ll dominate #ASCO25 too 💥
Smarter linkers, safer payloads, and dual-target precision are changing cancer therapy.
@OncoAlert @brunolarvol @Dr_Doc_ @FDAOncology @OncBrothers @JCO_ASCO @myESMO
#ADCs #CancerTherapy #ASCO25

💡 𝗔𝗗 𝗖𝗦 : comment effectuer la maintenance d'une autorité de certification ? 🔎 La base de votre CA occupe de plus en plus de place, et vous ne savez pas remédier à ce problème ? 🧷 Lien vers le chapitre : it-connect.fr/chapitres/ad-c… #ADCS #PKI #sysadmin #tuto

ITConnect_fr's tweet image. 💡 𝗔𝗗 𝗖𝗦 : comment effectuer la maintenance d'une autorité de certification ?

🔎 La base de votre CA occupe de plus en plus de place, et vous ne savez pas remédier à ce problème ? 

🧷 Lien vers le chapitre : it-connect.fr/chapitres/ad-c…

#ADCS #PKI #sysadmin #tuto

A summary of #ADCs and our research outputs, all in a digestible read #Gevena #surveys @UniNhantsFHES @UONPsyched

CallumECooper's tweet image. A summary of #ADCs and our research outputs, all in a digestible read #Gevena #surveys @UniNhantsFHES @UONPsyched
CallumECooper's tweet image. A summary of #ADCs and our research outputs, all in a digestible read #Gevena #surveys @UniNhantsFHES @UONPsyched

🔎 Windows Server : comment déployer une PKI à deux niveaux avec AD CS ? 👉 La réponse dans ce contenu signé Hugues Moccand : it-connect.fr/modules/ad-cs-… 📘 Retrouvez le cours complet AD CS en libre accès sur IT-Connect : it-connect.fr/cours/ad-cs-au… #ADCS #WindowsServer #elearning

ITConnect_fr's tweet image. 🔎 Windows Server : comment déployer une PKI à deux niveaux avec AD CS ?

👉 La réponse dans ce contenu signé Hugues Moccand : it-connect.fr/modules/ad-cs-…

📘 Retrouvez le cours complet AD CS en libre accès sur IT-Connect : it-connect.fr/cours/ad-cs-au…

#ADCS #WindowsServer #elearning
ITConnect_fr's tweet image. 🔎 Windows Server : comment déployer une PKI à deux niveaux avec AD CS ?

👉 La réponse dans ce contenu signé Hugues Moccand : it-connect.fr/modules/ad-cs-…

📘 Retrouvez le cours complet AD CS en libre accès sur IT-Connect : it-connect.fr/cours/ad-cs-au…

#ADCS #WindowsServer #elearning

From @myESMO advanced course on #ADCs meet the new kids on the block: ✅ Bi-specific/Bi-paratopic ADCs ✅ PDCs with peptide masks allowing payload cleavage by tumor proteases ✅ ISACS with TLR or STING agonist payload ✅ DACs degrading target through proteasome ubiquitin…

g_mountzios's tweet image. From @myESMO  advanced course on #ADCs meet the new kids on the block:

✅ Bi-specific/Bi-paratopic ADCs
✅ PDCs with peptide masks allowing payload cleavage by tumor proteases
✅ ISACS with TLR or STING agonist payload
✅ DACs degrading target  through proteasome ubiquitin…
g_mountzios's tweet image. From @myESMO  advanced course on #ADCs meet the new kids on the block:

✅ Bi-specific/Bi-paratopic ADCs
✅ PDCs with peptide masks allowing payload cleavage by tumor proteases
✅ ISACS with TLR or STING agonist payload
✅ DACs degrading target  through proteasome ubiquitin…
g_mountzios's tweet image. From @myESMO  advanced course on #ADCs meet the new kids on the block:

✅ Bi-specific/Bi-paratopic ADCs
✅ PDCs with peptide masks allowing payload cleavage by tumor proteases
✅ ISACS with TLR or STING agonist payload
✅ DACs degrading target  through proteasome ubiquitin…
g_mountzios's tweet image. From @myESMO  advanced course on #ADCs meet the new kids on the block:

✅ Bi-specific/Bi-paratopic ADCs
✅ PDCs with peptide masks allowing payload cleavage by tumor proteases
✅ ISACS with TLR or STING agonist payload
✅ DACs degrading target  through proteasome ubiquitin…

Student Love ❤ | CESP - ADCS Edition From practice labs to exam success - mastering AD CS! #CESP #ADCS #ActiveDirectory #RedTeam #CyberSecurity #CareerGrowth #AlteredSecurity

AlteredSecurity's tweet image. Student Love ❤ | CESP - ADCS Edition
From practice labs to exam success - mastering AD CS!

#CESP #ADCS #ActiveDirectory #RedTeam #CyberSecurity #CareerGrowth #AlteredSecurity

It was so nostalgic to give a talk at @LaStatale as alumni! Thank you @ADC_MI for inviting me back after more than 10 years to discuss past, present, and future of #ADCs

raffcolo's tweet image. It was so nostalgic to give a talk at @LaStatale as alumni! Thank you @ADC_MI for inviting me back after more than 10 years to discuss past, present, and future of #ADCs

What an amazing Plenary Session on #ADCs at #Targets25! 🔬✨@AACR Incredible discussions on dual payload ADCs, combo strategies with targeted therapies, and bridging biomarker gaps for smarter patient selection. Honored to be part of it—thank you to the organizers for the…

BrunaPellini's tweet image. What an amazing Plenary Session on #ADCs at #Targets25! 🔬✨@AACR 
Incredible discussions on dual payload ADCs, combo strategies with targeted therapies, and bridging biomarker gaps for smarter patient selection.

Honored to be part of it—thank you to the organizers for the…
BrunaPellini's tweet image. What an amazing Plenary Session on #ADCs at #Targets25! 🔬✨@AACR 
Incredible discussions on dual payload ADCs, combo strategies with targeted therapies, and bridging biomarker gaps for smarter patient selection.

Honored to be part of it—thank you to the organizers for the…
BrunaPellini's tweet image. What an amazing Plenary Session on #ADCs at #Targets25! 🔬✨@AACR 
Incredible discussions on dual payload ADCs, combo strategies with targeted therapies, and bridging biomarker gaps for smarter patient selection.

Honored to be part of it—thank you to the organizers for the…

No podemos finalizar por hoy sin mencionar la excelente labor como moderadora de la Dra. María Isabel Gallegos (Hospital General de Segovia). 💕 A lo largo de estos días continuaremos compartiendo lo más destacado de la reunión. #MamaCentroADCs2025 #ADCs

MamaCentro's tweet image. No podemos finalizar por hoy sin mencionar la excelente labor como moderadora de la Dra. María Isabel Gallegos (Hospital General de Segovia). 💕

A lo largo de estos días continuaremos compartiendo lo más destacado de la reunión.

#MamaCentroADCs2025
#ADCs

🔵 HER1/3 también entra en juego: •BL-B01D1 (TOPO-1): RR 41%, G3+ AE 52% 📌 Menos explorado, pero con datos iniciales prometedores. #BladderCancer #GUtrends25 #ADCs @Uromigos @OncoAlert @OncobitesTv @OncoReporte

TresUramigas's tweet image. 🔵 HER1/3 también entra en juego:
•BL-B01D1 (TOPO-1): RR 41%, G3+ AE 52%
📌 Menos explorado, pero con datos iniciales prometedores.
#BladderCancer #GUtrends25 #ADCs
@Uromigos @OncoAlert @OncobitesTv @OncoReporte

Loading...

Something went wrong.


Something went wrong.


United States Trends